435.00
-8.50
(-1.92%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 435.00 - 447.00 |
| 52 week | 235.00 - 455.00 |
| Open | 443.50 |
| Vol / Avg. | 2,439.00/20,000.00 |
| Mkt cap | 123.27M* |
| P/E | 42.60 |
| Div/yield | -/0.63 |
| EPS | 0.10* |
| Shares | 28.34M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q3 (Sep '12) | 2012 | |
| Net profit margin | 19.72% | 8.83% |
| Operating margin | 26.03% | 14.01% |
| EBITD margin | - | 32.43% |
| Return on average assets | 10.39% | 4.88% |
| Return on average equity | 12.85% | 6.54% |
| Employees | 324 | - |
| Carbon Disclosure Rating | - | - |
Address
Boldon Business Park, 10 Didcot Way
BOLDON, NE35 9PD
United Kingdom - Map
+44-191-5190660 (Phone)
+44-191-5190760 (Fax)
BOLDON, NE35 9PD
United Kingdom - Map
+44-191-5190660 (Phone)
+44-191-5190760 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Immunodiagnostic Systems Holdings plc (IDS) is engaged in manufacturing and distributing medical diagnostic products. The Company is also involved in research and development projects. The Company�s main operation is within the in vitro diagnostic (IVD) testing industry, supplying test kits to hospital and research laboratories. The Company is also engaged in the provision of immunoassay tests for the determination of vitamin D (both 25-Hydroxy and 1,25-Dihydroxy). The Company�s product include 1,25-Dihydroxy Vitamin D EIA, 1,25-Dihydroxy Vitamin D RIA, 25-Hydroxy Vitamin D EIA, 25-Hydroxy Vitamin D RIA ,Alpha CrossLaps (CTX-I) EIA, Automated IDS-iSYS System, BoneTRAP (TRAcP 5b) ELISA, Corticosterone EIA, Corticosterone HS EIA and CrossLaps for Culture (CTX-I) ELISA.
Officers and directors
| Patrik Olof Dahlen Ph.D. | Chief Executive Officer, Director | |
| Christopher Henry Francis Yates | Group Finance Director, Director | |
| Martha L. Garrity Ph.D. | Director - Technical, Executive Director | |
| Alain Rousseau | Director - Engineering, Executive Director | |
| Barry Hextall | Deputy Group Finance Director | |
| Anthony Francis Martin Ph.D. | Non-Executive Chairman of the Board | |
| Burkhard Wittek Ph.D. | Non-Executive Director | |
| Edward D. Blair Ph.D. | Independent Non-Executive Director | |
| Roland Sackers | Non-Executive Independent Director |